Pegylated Filgrastim vs. Filgrastim for Stem Cell Mobilization in Multiple Myeloma after Novel Agent Induction

The current standard of care for transplant-eligible myeloma patients is novel agent-based induction followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSC) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 9 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xianrui Zhang, Meiyun FangAbstractTEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential b...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Wasithep Limvorapitak, Michael Barnett, Donna Hogge, Donna Forrest, Thomas Nevill, Sujaatha Narayanan, Maryse Power, Stephen Nantel, Raewyn Broady, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, Alina Gerrie, Jennifer White, David SanfordAbstract (245 word of 250 words recommended)IntroductionOptimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia (AML) remains an area of ongoing research. We aimed to retrospectively compare outcomes following autoSCT with allogeneic SCT (allo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias JabbourAbstractThe widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of 
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions: 18F-FDG PET / CT helps to make FL patient’s treatment decisions by suggesting histological large cell transformation, clarifying clinical staging and finding treatment indications.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: In patients with relapsing or refractory DLBCL treated with R-DHAC salvage therapy followed by ASCT, pre-transplant 18-FDG PET/CT SUVmax and whole-body TLG remains the strongest predictive factors of PFS and OS. While a Deauville score of 5 also carries a dismal prognosis, a Deauville score of 4 does not appear to preclude a successful ASCT.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: The significant decrease in GSUVmean and GSUVmax of the MM patients in the HDT group seems to indicate that the aggressive treatment in these patients was successful in decreasing the number of myeloma lesions and possibly decreasing the incidence of insufficiency fractures, which can augment the uptake of NaF. Furthermore, chemotherapy can decrease the uptake of NaF, and as a result, high dose chemotherapy could have directly caused lower uptake of NaF. Further studies involving larger samples are needed to confirm our findings.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: A novel methodology was used to quantify bone marrow activity portrayed by FDG-PET/CT for the whole skeleton of MM patients. The significant decrease in GSUVmean and GSUVmax uptake from pre- to post-treatment in the HDT group shows that the high dose treatment was likely successful to significantly decrease the cancer cells in the bone marrow of those patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible,...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Filgrastim | Hematology | Leukemia | Lymphoma | Myeloma | Neulasta | Neupogen | Stem Cell Therapy | Stem Cells | Study | Transplants